CJC-1295 Without DAC: Mechanism of Action

Introduction

CJC-1295 without DAC (Modified GRF 1-29) is a tetrasubstituted synthetic analog of human growth hormone-releasing hormone (GHRH). Its reported mechanism of action centers on activation of the pituitary growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary gland. This article reviews the published molecular pharmacology of GHRH-R signaling and the specific evidence relevant to CJC-1295 without DAC and its structural predecessors, drawing on peer-reviewed primary literature. Findings described are from preclinical and early-phase human research contexts.

Receptor Target and Signaling Pathway

The GHRH receptor (GHRH-R) is a class B G protein-coupled receptor (GPCR) with seven transmembrane-spanning domains. In anterior pituitary somatotroph cells, GHRH-R is coupled primarily to the stimulatory G protein subunit Gαs. A 2025 review by Szalai and colleagues, published in Reviews in Endocrine and Metabolic Disorders, described the canonical GHRH-R activation cascade in detail: agonist binding to the extracellular ligand-binding domain of GHRH-R leads to receptor conformational change, Gαs dissociation from the heterotrimeric G protein complex, and activation of adenylyl cyclase [1].

Adenylyl cyclase activation results in the conversion of ATP to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor cAMP response element-binding protein (CREB). Phosphorylated CREB, in turn, drives transcription of the pituitary-specific transcription factor Pit-1 and downstream growth hormone (GH) gene expression [1].

Alongside the cAMP-PKA-CREB transcriptional axis, GHRH-R activation also triggers calcium influx through voltage-gated calcium channels in the somatotroph plasma membrane. This calcium entry directly stimulates exocytosis of pre-formed GH-containing secretory granules, accounting for the acute GH secretory response that precedes any change in GH gene transcription [1]. The Szalai review also identified secondary signaling through mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, which mediate somatotroph cell proliferation responses to sustained GHRH-R stimulation and are regarded as complementary to the cAMP axis for acute GH secretion. This GHRH-R signaling cascade is mechanistically distinct from the intracellular calcium pathway engaged by GHS-R agonists such as GHRP-2, which activate the ghrelin receptor through a separate receptor family.

Reported Molecular Interactions

CJC-1295 without DAC interacts with GHRH-R through the same N-terminal binding determinants as native GHRH and its 29-amino acid fragment sermorelin. The four amino acid substitutions that distinguish CJC-1295 without DAC from the native GRF(1-29) sequence — D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu (Nle) at position 27 — were designed to confer resistance to enzymatic cleavage rather than to alter receptor binding affinity or intrinsic efficacy at GHRH-R [2].

The position-2 D-Ala substitution is the most pharmacologically consequential modification in this series. In the native hGRF(1-29) sequence, the N-terminal Tyr¹-Ala² bond is recognized and cleaved by dipeptidyl peptidase-4 (DPP-4), generating the biologically inactive fragment GRF(3-29). Frohman and colleagues demonstrated in 1989 that DPP-4 cleavage is the dominant metabolic inactivation pathway for plasma GHRH [3]. Substitution of L-Ala² with D-Ala² creates a peptide bond geometry that DPP-4 cannot productively engage, conferring in vitro resistance to N-terminal cleavage. The position-27 Nle substitution eliminates the methionine residue that is susceptible to oxidative modification, improving chemical stability during storage and in the oxidative plasma environment.

Jetté and colleagues (2005) characterized the in vitro stability properties of a series of hGRF(1-29) albumin bioconjugates that incorporate the same tetrasubstituted scaffold as CJC-1295 without DAC [2]. The study reported enhanced stability of these tetrasubstituted analogs against DPP-4 cleavage in bovine plasma and confirmed retained bioactivity in GH secretion assays using cultured rat anterior pituitary cells. Critically for understanding CJC-1295 without DAC, the Jetté study demonstrated that the non-bioconjugated (DAC-free) forms retained GHRH-R agonist activity — establishing that the tetrasubstituted scaffold itself is biologically active at the GHRH receptor, independent of any albumin-binding contribution. These findings confirm that the preclinical data support the tetrasubstituted framework as preserving GHRH-R agonist activity while conferring metabolic stability relative to the unmodified sequence.

Downstream Effects in Research Models

The downstream consequence of GHRH-R activation by CJC-1295 without DAC — as characterized through research on structurally analogous compounds — is stimulation of somatotroph GH synthesis and secretion. Because CJC-1295 without DAC lacks the albumin-binding DAC moiety, its pharmacokinetic profile differs substantially from CJC-1295 with DAC: without albumin conjugation, the compound is subject to renal filtration and residual proteolytic clearance, yielding a plasma half-life on the order of 30 minutes, compared to approximately eight days for the albumin-bound DAC variant.

Research on GHRH-R physiology indicates that discrete, pulsatile exposure of somatotrophs to GHRH agonism — as occurs with endogenous hypothalamic GHRH release — produces episodic GH pulses consistent with the normal architecture of pulsatile GH secretion. Ionescu and Frohman (2006), studying CJC-1295 with DAC in healthy adults, reported that pulsatile GH secretory patterns were preserved even under conditions of sustained GHRH-R agonist exposure, with changes in pulse amplitude rather than loss of pulsatile architecture — a finding attributed to intact somatostatinergic counter-regulation [4]. This mechanistic observation has been cited in discussions of how shorter-acting GHRH analogs such as CJC-1295 without DAC may relate to physiological GH pulse generation.

Alba and colleagues (2006), in a preclinical study using GHRH knockout mice, reported that once-daily administration of CJC-1295 (employing the same tetrasubstituted core structure) was associated with body weight and linear growth measurements within the normal range for wild-type controls, in animals lacking endogenous GHRH signaling [5]. The authors attributed this effect to restoration of intermittent pituitary GH secretory stimulation and interpreted the results as evidence of the biological relevance of GHRH-R agonism in models of GHRH deficiency. These preclinical observations are cited in the research literature as supporting the mechanistic framework for GHRH-R agonism; they do not establish efficacy or safety in any human clinical context.

Areas of Ongoing Investigation

The published literature identifies several mechanistic questions that represent active areas of investigation for the CJC-1295 without DAC scaffold. The precise receptor-level pharmacology at human GHRH-R — including binding affinity constants (Ki), functional potency (EC50), and any agonist bias relative to native GHRH or sermorelin — is an area where dedicated study of this specific compound would extend the existing data derived from structurally related analogs and the broader GHRH-R pharmacology literature.

The interaction between GHRH-R signaling and the counter-regulatory somatostatin system under short-acting GHRH analog exposure represents an additional research frontier. Native hypothalamic GHRH release is tightly coupled to somatostatinergic inhibition in an ultradian rhythm; published evidence on CJC-1295 with DAC [4] has informed mechanistic understanding of this interaction under prolonged agonism, and study of the without-DAC variant's shorter pharmacodynamic profile would complement this foundation.

The Szalai 2025 review notes that GHRH-R splice variants are expressed in multiple extrapituitary tissues — including cardiac and immune tissue — and may engage distinct signaling outputs upon agonist stimulation [1]. The characterization of these extrapituitary receptor responses to GHRH analogs represents an emerging area of investigation in the field.

As with all research-use compounds, mechanistic characterizations derived from in vitro cell assays and animal model studies do not establish the mechanism of action in humans. These open research questions represent the frontier of GHRH-R agonist pharmacology rather than fundamental uncertainties about the compound's core signaling biology, which is well-established in the primary literature. The published studies informing this mechanistic framework are surveyed in the CJC-1295 without DAC published research article. Verified research-grade CJC-1295 without DAC from SpartaLabs is accompanied by HPLC purity data and mass spectrometry confirmation for each batch.

References

1. Szalai M, Kandrács Á, Vass RA, et al. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;26:343-352. DOI: 10.1007/s11154-025-09952-x. PMC: PMC12137518

2. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669. DOI: 10.1210/en.2004-1286

3. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. PMID: 2651468. DOI: 10.1172/JCI114049. PMC: PMC303858

4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654. DOI: 10.1210/jc.2006-1702

5. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID: 16822960. DOI: 10.1152/ajpendo.00201.2006